Agios Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $58 price target The firm views the company’s lead ...
What is HC Wainwright’s Estimate for Prothena Q4 Earnings?
Investment analysts at HC Wainwright issued their Q4 2025 EPS estimates for Prothena in a research note issued to investors on Friday, February 21st. HC Wainwright analyst A. Fein expects that the ...
Benitec Biopharma’s (BNTC) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC – Free Report) in a research report sent ...